Home

A New Solution
to Quit Smoking and Vaping

29M

Smokers in the US

11M

E-Cigs in the US

Nicotine Addiction Is Not a Problem of the Past

Smoking is still a global public health threat and despite having medication for decades, we’ve yet to eradicate this global epidemic.

1/3

of cancer deaths in the U.S. are attributed to cigarette smoking

8M

U.S. Deaths Nationwide

16M

Americans Live with Smoking- Related Disease

Let’s face it. Current treatments are failing. We’re here to change that.

While the majority of people who smoke in the US say they would like to quit and more than half make an attempt, only a tiny percentage of quit attempts are successful. No new smoking cessation treatments have been FDA approved since 2006. With only two non-nicotine FDA-approved smoking cessation treatments, there are still no approved treatments specifically for e-cigarette smoking cessation.

Introducing

Cytisinicline

Derived from natural sources, cytisinicline is a potential new treatment for nicotine dependence, including smoking and vaping.

Helping smokers quit… with minimal side effects

In a recent trial, cytisinicline has been shown to effectively help even highly dependent smokers stop smoking. Cytisinicline binds to the same receptors as nicotine to reduce both withdrawal symptoms and satisfaction associated with smoking. And since it doesn’t bind as strongly to certain receptors, it is believed to have less potential to cause side effects—including nausea and vomiting.

90%

Trial participants had over 90% compliance with cytisinicline treatment

About Achieve

Achieve is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine dependence.

Latest

 

Achieve Life Sciences Announces Completion of Enrollment in ORCA-OL Clinical Trial & Successful Outcome of the First Data Safety Monitoring Committee Meeting

SEATTLE, Wash and VANCOUVER, British Columbia, October 10, 2024 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Na

Read More

Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs

SEATTLE, Wash and VANCOUVER, British Columbia, October 1, 2024 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nas

Read More

Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors

Richard Stewart reassumes role of Chief Executive Officer Thomas King appointed Executive Chairman of the Board of Direc

Read More

Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Company to host conference call at 4:30 PM EDT today, Tuesday, August 13, 2024 SEATTLE, Wash and VANCOUVER, British Colu

Read More

We can’t help but

Believe

And we’re looking for others like us who believe we can bring an end to this fight.
Will you join us?

  • US Headquarters
  • 22722 29th Dr SE, Suite 100
  • Bothell, WA 98021
  • Phone: (425) 686-1500
  • Vancouver Office
  • 1040 W Georgia Street, Suite 1030
  • Vancouver, BC V6E 4H1